IP Library › Patent Application 11464447
Patent Application
App. No. 11/464,447

ANTI-CD80 ANTIBODY HAVING ADCC ACTIVITY FOR ADCC MEDIATED KILLING OF B CELL LYMPHOMA CELLS ALONE OR IN COMBINATION WITH OTHER THERAPIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/464,447
Abstract

Methods for treating B cell malignancies, in particular B cell leukemia and lymphoma, using an anti-CD80 antibody alone or in combination with an anti-CD20 antibody or chemotherapy is provided. These methods result in a synergistic anti-tumor response.

Claims (21)

1 . A method for potentiating the ADCC and/or CDC activity of an anti-CD80 (B7.1) antibody against CD80 positive cells by administering said anti-CD80 antibody in combination with an anti-CD20 antibody.

2 . The method of claim 1 wherein said antibodies are administered in either order or together.

3 . The method of claim 2 wherein the anti-CD20 antibody is administered first.

4 . The method of claim 2 wherein the anti-CD80 antibody is administered first.

5 . The method of claim 1 wherein the anti-CD80 antibody is a human, humanized or chimeric antibody containing human constant regions.

6 . The method of claim 5 wherein said anti-CD80 antibody contains human IgG 1 or IgG 3 constant regions.

7 . The method of claim 1 wherein the anti-CD20 antibody is Rituxan®.

8 . The method of claim 1 wherein the anti-CD80 antibody is IDEC-114.

9 . A method of treating B cell malignancy comprising administering a therapeutically effective amount of an anti-CD80 antibody.

10 . The method of claim 9 wherein said antibody is a human, humanized or chimeric antibody containing human constant regions.

11 . The method of claim 10 wherein said constant regions are human IgG 1 or IgG 3 constant regions.

12 . The method of claim 9 wherein said antibody binds the same epitope as IDEC-114 or competes with IDEC-114 for binding to CD80.

13 . The method of claim 9 wherein said antibody exhibits ADCC and/or CDC activity against B cell lymphoma cells.

14 . The method of claim 9 wherein said antibody is IDEC-114.

15 . The method of claim 9 wherein said B cell malignancy is a B cell lymphoma or leukemia.

16 . The method of claim 15 wherein said B cell malignancy is a B cell lymphoma.

17 . The method of claim 16 wherein said B cell lymphoma is selected from the group consisting of Hodgkin's lymphoma, non-Hodgkin's lymphoma, low grade/follicular non-Hodgkin's lymphoma (NHL), cell lymphoma (FCC), mantle cell lymphoma (MCL), diffuse large cell lymphoma (DLCL), small lymphocyte (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small non-cleaved cell NHL, bulky disease NHL and Waldenstrom's Macroglobulinemia.

18 . The method of claim 16 wherein said leukemia is ALL-L3 (Burkitt's type leukemia), chronic lymphocytic leukemia (CLL) and monocytic cell leukemia.

19 . The method of claim 17 wherein said lymphoma is a non-Hodgkin's lymphoma.

20 . A combination therapy for the treatment of a B cell malignancy comprising administering a therapeutically effective amount of an anti-CD80 antibody and an anti-CD20 antibody.

21 - 51 . (canceled)